Mauricio Naoto Saheki

Mauricio Naoto Saheki

Auto-generated profile, based on publicly available information

Mauricio Naoto Saheki

ORCID http://orcid.org

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Acta Tropica
Verified
Journal Article
Closed access
AOA.G.L. Oliveira
A.G.L. Oliveira
PBPatricia Dias Brito
Patricia Dias Brito
ASA.O. Schubach
A.O. Schubach
RORaquel de Vasconcellos Carvalhaes de Oliveira
Raquel de Vasconcellos Carvalhaes de Oliveira
MSM.N. Saheki
M.N. Saheki
CVC.M. Valete-Rosalino
C.M. Valete-Rosalino

30 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMauricio Naoto Saheki
Mauricio Naoto Saheki
MLMarcelo Rosandiski Lyra
Marcelo Rosandiski Lyra
SBSandro Javier Bedoya-Pacheco
Sandro Javier Bedoya-Pacheco
LALiliane de Fátima Antônio
Liliane de Fátima Antônio
MPMaria Inês Fernandes Pimentel
Maria Inês Fernandes Pimentel
ASArmando de Oliveira Schubach
Armando de Oliveira Schubach
Although high dose of antimony is the mainstay for treatment of American cutaneous leishmaniasis (ACL), ongoing major concerns remain over its toxicity. Whether or not low dose antimony regimens provide non-inferior effectiveness and lower toxicity has long been a question of dispute. A single-blind, non-inferiority, randomized controlled trial was conducted comparing high dose with low dose of antimony in subjects with ACL treated at a referral center in Rio de Janeiro, an endemic area of Leishmania (Viannia) braziliensis transmission. The primary outcome was clinical cure at 360 days of follow-up in the modified-intention-to-treat (mITT) and per-protocol (PP) populations. Non-inferiority margin was 15%. Secondary objectives included occurrence of epithelialization, adverse events and drug discontinuations. This study was registered in ClinicalTrials.gov: NCT01301924. Overall, 72 patients were randomly assigned to one of the two treatment arms during October 2008 to July 2014. In mITT, clinical cure was observed in 77.8% of subjects in the low dose antimony group and 94.4% in the high dose antimony group after one series of treatment (risk difference 16.7%; 90% CI, 3.7–29.7). The results were confirmed in PP analysis, with 77.8% of subjects with clinical cure in the low dose antimony group and 97.1% in the high dose antimony group (risk difference 19.4%; 90% CI, 7.1–31.7). The upper limit of the confidence interval exceeded the 15% threshold and was also above zero supporting the hypothesis that low dose is inferior to high dose of antimony after one series of treatment. Nevertheless, more major adverse events, a greater number of adverse events and major adverse events per subject, and more drug discontinuations were observed in the high dose antimony group (all p<0.05). Interestingly, of all the subjects who were originally allocated to the low dose antimony group and were followed up after clinical failure, 85.7% achieved cure after a further treatment with local therapy or low dose of antimony. Compared with high dose, low dose of antimony was inferior at the pre-specified margin after one series of treatment of ACL, but was associated with a significantly lower toxicity. While high dose of antimony should remain the standard treatment for ACL, low dose antimony treatment might be preferred when toxicity is a primary concern.

1 January 2016 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
MLMarcelo Rosandiski Lyra
Marcelo Rosandiski Lyra
SPSonia Regina Lambert Passos CAPES 88881 130793 Passos
Sonia Regina Lambert Passos CAPES 88881 130793 Passos
Maria Inês Fernandes PimentelMaria Inês Fernandes Pimentel
Maria Inês Fernandes Pimentel
SBSandro Javier Bedoya-Pacheco
Sandro Javier Bedoya-Pacheco
CVCláudia Maria Valete-Rosalino
Cláudia Maria Valete-Rosalino
ASArmando Oliveria Schubach
Armando Oliveria Schubach
American tegumentary leishmaniasis is an infectious disease caused by a protozoan of the genus Leishmania. Pentavalent antimonials are the first choice drugs for cutaneous leishmaniasis (CL), although doses are controversial. In a clinical trial for CL we investigated the occurrence of pancreatic toxicity with different schedules of treatment with meglumine antimoniate (MA). Seventy-two patients were allocated in two different therapeutic groups: 20 or 5 mg of pentavalent antimony (Sb5+)/kg/day for 20 or 30 days, respectively. Looking for adverse effects, patients were asked about abdominal pain, nausea, vomiting or anorexia in each medical visit. We performed physical examinations and collected blood to evaluate serum amylase and lipase in the pre-treatment period, and every 10 days during treatment and one month post-treatment. Hyperlipasemia occurred in 54.8% and hyperamylasemia in 19.4% patients. Patients treated with MA 20 mg Sb5+ presented a higher risk of hyperlipasemia (p = 0.023). Besides, higher MA doses were associated with a 2.05 higher risk ratio (p = 0.003) of developing more serious (moderate to severe) hyperlipasemia. The attributable fraction was 51% in this group. Thirty-six patients presented abdominal pain, nausea, vomiting or anorexia but only 47.2% of those had hyperlipasemia and/ or hyperamylasemia. These findings suggest the importance of the search for less toxic therapeutic regimens for the treatment of CL.

1 December 2008 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
MSMauricio Naoto Saheki
Mauricio Naoto Saheki
ASArmando de Oliveira Schubach
Armando de Oliveira Schubach
MSMariza de Matos Salgueiro
Mariza de Matos Salgueiro
FCFátima Conceição-Silva
Fátima Conceição-Silva
BWBodo Wanke
Bodo Wanke
MLMárcia Lazera
Márcia Lazera
É relatado um caso de histoplasmose cutânea primária em um homem de 45 anos, com apresentação de um nódulo eritematoso no dorso da mão direita acompanhado de linfadenomegalia regional indolor, que se desenvolveu após trauma local ocorrido durante treinamento militar em túnel habitado por morcegos. O exame histológico de biópsia da lesão cutânea mostrou um infiltrado granulomatoso, porém não evidenciou elementos fúngicos. O cultivo deste material incubado em Ágar Sabouraud mostrou crescimento de Histoplasma capsulatum. Não foi encontrada evidência de envolvimento sistêmico ou imunossupressão. O tratamento com 400mg diários de itraconazol oral durante 6 meses resultou na remissão completa da lesão, mantida um ano após o término do tratamento.

1 April 2011 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
MPMaria Inês Fernandes Pimentel
Maria Inês Fernandes Pimentel
CBCibele Baptista
Cibele Baptista
ÉRÉvelyn Figueiredo Rubin
Évelyn Figueiredo Rubin
ÉVÉrica de Camargo Ferreira e Vasconcellos
Érica de Camargo Ferreira e Vasconcellos
MLMarcelo Rosandiski Lyra
Marcelo Rosandiski Lyra
ASArmando de Oliveira Schubach
Armando de Oliveira Schubach
This is a case report of a Brazilian soldier with cutaneous leishmaniasis. The lesion relapsed following two systemic treatments with meglumine antimoniate. The patient was treated with amphotericin B, which was interrupted due to poor tolerance. Following isolation of Leishmania sp., six intralesional infiltrations of meglumine antimoniate resulted in no response. Leishmania sp promastigotes were again isolated. The patient was submitted to intramuscular 4mg/kg pentamidine. Parasites from the first and second biopsies were identified as Leishmania (Viannia) braziliensis; those isolated from the first biopsy were more sensitive to meglumine antimoniate in vitro than those isolated from the second biopsy. No relapse was observed.

1 December 2014 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
MLMarcelo Rosandiski Lyra
Marcelo Rosandiski Lyra
LALiliane De Fátima Antonio
Liliane De Fátima Antonio
AVAndréa Gina Varon
Andréa Gina Varon
MPMaria Inês Fernandes Pimentel
Maria Inês Fernandes Pimentel
LOLiliane de Fátima Antonio Oliveira
Liliane de Fátima Antonio Oliveira
AVAntonio Carlos Francesconi Do Valle
Antonio Carlos Francesconi Do Valle
We report 2 cases of patients with immune reconstitution inflammatory syndrome (IRIS) associated with cutaneous disseminated sporotrichosis and human immunodeficiency virus (HIV) coinfection. The patients received specific treatment for sporotrichosis. However, after 4 and 5 weeks from the beginning of antiretroviral therapy, both patients experienced clinical exacerbation of skin lesions despite increased T CD4+ cells (T cells cluster of differentiation 4 positive) count and decreased viral load. Despite this exacerbation, subsequent mycological examination after systemic corticosteroid administration did not reveal fungal growth. Accordingly, they were diagnosed with IRIS. However, the sudden withdrawal of the corticosteroids resulted in the recurrence of IRIS symptoms. No serious adverse effects could be attributed to prednisone. We recommend corticosteroid treatment for mild-to-moderate cases of IRIS in sporotrichosis and HIV coinfection with close follow-up.